

Draft National Vaccine Plan Stakeholders Meeting

Facilitated by Dr. Corry Dekker, CDR Angela Shen,
Jovonni Spinner

Morning session: by Goal #1

Afternoon session: by Sector



Goal 1: Develop new and improved vaccines

- 1.1 Prioritize needs
- broad consensus and support
- Support NVPO commission appropriate body (e.g. IOM) to include all stakeholders
- Cornerstone of the goal
- Linkage to benefits of development of priority vaccines (e.g. addressing barriers such as regulatory approval, streamline acip recommendations, reimbursement)

Objective 1.2 - Develop new vaccine candidates and improve current vaccines

- Separate out develop new and improve current vaccines Sensitivities to phrasing (e.g. “optimize” vs “improve” vaccines)
- Felt strongly about Maternal Immunizations and felt there should be an indicator addressing (workshop to discuss barriers to developing these vaccines)
- Needed discussion on development of vaccines where the benefit of the vaccine is not realized by the one being vaccinated

1.3 Research on novel delivery methods

1. Clarify delivery – as physical method of administering vaccines

1.4 Dev vaccine candidates and scientific tools for licensure

- Reordered in a more logical sense and aligned with regulatory timeline
- Clarify language – e.g. having a process for manufacturing clinical grade material ie contract manufacturing for

1.5 Host immune response

- Clarify this section and call out a role for genomics

1.6 Science base for development and licensure

- Link this section to safety as a whole and clarify that pre-licensure safety should also inform post-licensure safety (i.e. hand off of safety information)

Indicators – slide 1

- Within one year, create an evidence based list of new vaccine targets to prevent infectious diseases that are high priorities for development.
- Strengthen the wording and link to “promises” ie implementation accountability and funding
- Identify **X** candidate vaccines (e.g. for HIV, malaria, TB and a cross protective vaccine for Influenza) and advance **Y** priority vaccine candidates along the research and development pipeline including **Z** candidates into advanced clinical trials. -- delete

Indicators – Slide 2

- *Advance **X** new delivery strategies that will improve effectiveness, feasibility, acceptability, safety or ease of administration of new or improved vaccines into clinical trials.*
- *In **X** years, have the capability to test potential vaccine candidates in clinical trials developed in response to an emerging infectious disease health threat within six months of the identification of the need for a vaccine.*

PM Session – Vaccine Industry, HIDA, Consumers/Parents

- Report card – Two companies compare current and future planned activities against the plan
- Funding and implementation critical – if USG commits the importance as well as funds, then other stakeholders tend to follow (e.g. Pandemic Influenza)
- Political commitment/Higher ups – Importance of top level administration

Next Steps

- Do we need to meet again?

Important to see another round of the draft before it becomes final. Request for more time to get stakeholder input